Two Sigma Advisers’s Pharvaris PHVS Stock Holding History

Two Sigma Advisers’s Portfolio PHVS Stock Details PHVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-89,600	Closed	-$2.49M	–	1572
2025 Q4	$2.49M	Buy	+89,600	New	+$2.16M	﹤0.01%	1093

Other funds holding PHVS

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

EFM

EQT Fund Management Luxembourg $1.02B AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Two Sigma Advisers's PHVS Position: Q1 2026 in Review

Two Sigma Advisers sold out of Pharvaris (PHVS) in Q1 2026, closing a stake of 89,600 shares — an estimated $2.49M sold.

Two Sigma Advisers first reported a position in PHVS in Q4 2025 and held it in 1 quarter. The position peaked at $2.49M in Q4 2025. 110 funds tracked by Wall St. Rank hold PHVS as of Q1 2026.

Two Sigma Advisers reported no remaining Pharvaris position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 89,600 Pharvaris shares in Q1 2026, an estimated $2.49M.
Two Sigma Advisers first reported a position in Pharvaris in Q4 2025 and held it in 1 quarter.
Two Sigma Advisers's Pharvaris position peaked at $2.49M in Q4 2025.
110 funds tracked by Wall St. Rank held Pharvaris as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.